Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade
Kartik Sehgal(Beth Israel Deaconess Medical Center), David A. Barbie(Dana-Farber Cancer Institute), Peter S. Hammerman(Broad Institute), Silvia Goldoni(Novartis (Switzerland)), Moataz Noureddine(Dana-Farber Cancer Institute), Maria Pinzon-Ortiz, Tetsuo Tani(Keio University), Russell W. Jenkins(Broad Institute), Paul T. Kirschmeier(Brigham and Women's Hospital), Carino Gurjao(Broad Institute), Marios Giannakis(Broad Institute), Tyler J. Teceno(Dana-Farber Cancer Institute), Luke J. Taus(Dana-Farber Cancer Institute), Cloud P. Paweletz(Massachusetts General Hospital), Shunsuke Kitajima(Japanese Foundation For Cancer Research), Tran C. Thai(Dana-Farber Cancer Institute), Derek Liu(Harvard–MIT Division of Health Sciences and Technology), Elena V. Ivanova(Massachusetts General Hospital), Patrick H. Lizotte(Harvard University), Andrew Portell(Massachusetts General Hospital), Prafulla C. Gokhale(Harvard University), Amir Vajdi(Dana-Farber Cancer Institute), Navin R. Mahadevan(Brigham and Women's Hospital), Jonathan Greene(Claremont Graduate University), David Liu(University of Louisville), Juan J. Miret(Dana-Farber Cancer Institute), William D. Hastings(Brigham and Women's Hospital), Christie J. Lau(Dana-Farber Cancer Institute)
Cited by 73
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k